Pre-specified secondary analysis of FLOW in type 2 diabetes and CKD: semaglutide vs placebo reduced infection SAEs, infection hospitalisation or death (HR 0.79), with greater benefit with HbA1c >8% and UACR ≥2000 mg/g; infection SAEs 17.9% vs 21.3%.
Secondary analysis
Rayner et al. Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial